Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px
Document › Details

Alligator Bioscience AB. (3/22/23). "Press Release: Alligator Intends to Carry Out a 91 Percent Secured Rights Issue of Units of Approximately SEK 199 Million [Not for US, AU, et al.]".

Organisations Organisation Alligator Bioscience AB (Nasdaq Stockholm: ATORX)
  Group Alligator Bioscience (Group)
  Organisation 2 Redeye AB
Products Product ALG.APV-527 (Alligator Bioscience / Aptevo Therapeutics)
  Product 2 mitazalimab (ADC-1013)
Index term Index term Alligator Bioscience–SEVERAL: investment, 202303– rights issue up to SEK199m shares plus up to approx SEK22m warrants, if exercised
Person Person Bregenholt, Søren (Alligator Bioscience 202106– CEO before Macrophage Pharma + Novo Nordisk + Symphogen)
     


   
Record changed: 2024-01-20

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Alligator Bioscience (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px




» top